3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
4
Other neoplasm
2
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Conditions
Leukemia, Myeloid, Acute
394
Precursor Cell Lymphoblastic Leukemia-Lymphoma
226
Hematologic Neoplasms
206
Leukemia, Lymphocytic, Chronic, B-Cell
175
Myelodysplastic Syndromes
144
Leukemia
125
Lymphoma
90
Lymphoma, Non-Hodgkin
76
Multiple Myeloma
67
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
67
Recurrence
55
Neoplasms
53
Leukemia, Myelomonocytic, Chronic
50
Burkitt Lymphoma
44
Lymphoma, Large B-Cell, Diffuse
41
Leukemia, Biphenotypic, Acute
41
Myeloproliferative Disorders
39
Lymphoma, Mantle-Cell
39
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
37
Hodgkin Disease
36
Lymphoma, B-Cell
32
Lymphoma, Follicular
31
Leukemia, B-Cell
27
Lymphoma, B-Cell, Marginal Zone
24
Anemia, Refractory, with Excess of Blasts
24
Waldenstrom Macroglobulinemia
23
Primary Myelofibrosis
21
Myelodysplastic-Myeloproliferative Diseases
20
Hematologic Diseases
19
Lymphoma, T-Cell
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Diseases
×
Other hematologic neoplasm
×
90 days
×
Clear all
NCT04996875
2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2
Recruiting
140 enrolled